Advanced Genetic Technologies
2006
FOUNDED
M&A
STATUS
M&A
LATEST DEAL TYPE
1
FINANCING ROUNDS
Description
Developer of technologies for immune therapy to address the problem of multidrug resistant strains of HIV. The company holds the exclusive licenses for monoclonal antibodies TS1-18 and TS1-22 and non-exclusive rights to the bacterial plasmid 8630.
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Acquirer
Primary Office
- 2109 East Palm Avenue
- Tampa, FL 33605
- United States
Advanced Genetic Technologies Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Advanced Genetic Technologies‘s full profile, request access.
Request full access to PitchBookAdvanced Genetic Technologies Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Advanced Genetic Technologies‘s full profile, request access.
Request full access to PitchBookAdvanced Genetic Technologies Executive Team (2)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| Timothy Springer Ph.D | Founder |
1 Former Executive
You’re viewing 1 of 2 executives. Get the full list »